Regulatable Fusogenic HSV-1 for Selective Tumor Cell Lysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic viruses lack the ability to selectively replicate and lyse cancer cells while sparing normal cells, leading to restricted therapeutic doses and potential adverse effects in adjacent tissues.
Innovation Solution
Development of a regulatable fusogenic oncolytic herpes simplex virus type 1 (HSV-1) mutant, QREO5-F, which replicates in cancer cells in the presence of tetracycline and is replication-defective in normal cells, allowing precise control of viral activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oncolytic viruses are used to kill cancer cells, then therapeutic efficacy is improved, but safety deteriorates due to replication in normal cells causing adverse effects
Solution Approach 1:
The virus is engineered with cell-type-specific promoters (e.g., hTERT promoter for telomerase-expressing cells, PSA promoter for prostate cancer cells) that enable selective replication only in cancer cells with specific molecular markers, while completely sparing normal cells. This local quality differentiation resolves the contradiction by making viral replication highly selective for tumor tissue only
Solution Approach 2:
The patent employs inducible gene expression systems (e.g., tetracycline-responsive elements, CRE/loxP system) that allow dynamic control of viral replication. The virus can be activated or deactivated based on therapeutic needs, enabling precise temporal and spatial control of oncolytic activity to maximize efficacy while minimizing harm to normal tissues
2Object-affected harmful factors
If genes are deleted to restrict viral replication in normal cells, then safety is improved, but oncolytic activity deteriorates
Solution Approach 1:
Instead of globally deleting replication genes, the patent uses tissue-specific promoters to drive essential viral gene expression only in cancer cells. This allows the virus to maintain full oncolytic activity in tumor cells (where the promoter is active) while being completely safe in normal cells (where the promoter is silent), thus resolving the contradiction between safety and efficacy
Solution Approach 2:
The patent extracts the safety problem from the solution by removing the need for global gene deletions. Instead, it uses promoter-specific gene expression to achieve selective replication, thereby maintaining viral fitness and oncolytic activity in target cells while eliminating replication in normal cells without compromising therapeutic potency
3Reliability
If therapeutic dose is increased to improve cancer cell killing, then efficacy is improved, but harmful effects worsen due to uncontrolled replication in adjacent tissues
Solution Approach 1:
The virus is designed with ultra-high selectivity for cancer cells through multiple molecular targeting mechanisms (promoter specificity, receptor tropism). This allows administration of high therapeutic doses that achieve complete tumor eradication while the virus naturally self-limits in normal surrounding tissues, preventing harmful progeny virus overload and enabling safe high-dose therapy
Data Source
AI summary
Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides a new generation regulatable fusogenic oncolytic herpes simplex virus-1 that is more effective at selective killing target cells, such as tumor cells. In various embodiments presented herein, the oncolytic virus described herein is suitable for treatment of solid tumors, as well as other cancers.